Enliven Therapeutics Future Growth
Future criteria checks 2/6
Enliven Therapeutics's earnings are forecast to decline at 18.7% per annum while its annual revenue is expected to grow at 87.4% per year. EPS is expected to decline by 12% per annum.
Key information
-18.7%
Earnings growth rate
-12.0%
EPS growth rate
| Pharmaceuticals earnings growth | 23.9% |
| Revenue growth rate | 87.4% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 14 Nov 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -145 | -77 | -77 | 5 |
| 12/31/2025 | 0 | -113 | -75 | -89 | 6 |
| 12/31/2024 | N/A | -91 | -68 | -74 | 6 |
| 9/30/2024 | N/A | -85 | -69 | -68 | N/A |
| 6/30/2024 | N/A | -83 | -72 | -72 | N/A |
| 3/31/2024 | N/A | -80 | -64 | -64 | N/A |
| 12/31/2023 | N/A | -72 | -61 | -61 | N/A |
| 9/30/2023 | N/A | -62 | -57 | -57 | N/A |
| 6/30/2023 | N/A | -52 | -48 | -47 | N/A |
| 3/31/2023 | N/A | -44 | -43 | -43 | N/A |
| 12/31/2022 | N/A | -38 | -33 | -32 | N/A |
| 9/30/2022 | N/A | -37 | -31 | -31 | N/A |
| 12/31/2021 | N/A | -25 | -19 | -19 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ELVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ELVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ELVN's revenue (87.4% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: ELVN's revenue (87.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELVN's Return on Equity is forecast to be high in 3 years time